Rheumatoid Arthritis

In Rheumatoid Arthritis (RA), the most common chronic inflammatory joint disease, autoantibodies attack the joints and cause joint destruction. Below are COVID news and research updates that specifically relate to RA.

Molnupiravir & Nirmatrelvir/Ritonavir in the Treatment of Systemic Autoimmune Rheumatic Diseases

Molnupiravir (MP) and Nirmatrelvir/ritonavir (NM/R) were the first two orally administered antiviral drugs authorized to treat COVID-19. However, the last two phases of clinical trials testing MP and NM/R in COVID-19 were conducted in unvaccinated individuals and before the emergence of the Omicron variant. Additionally, clinical trials didn’t include people suffering from systemic autoimmune rheumatic diseases (SARDs).

Read More »

Caring for Autoimmunity & Long COVID with a Personalized Approach

The company Mymee recently published a study on their personalized digital care program for patients living with autoimmune diseases as well as long Covid. Researchers found that over 85% of patients with moderate to severe symptoms saw improvements with their anxiety, depression, fatigue, pain interference, sleep disturbance, and pain intensity while increasing cognitive and physical function.

Read More »

How COVID-19 Triggers an Autoimmune Reaction

Researchers have hypothesized how a Covid-19 infection may trigger the development of autoimmune diseases through three different mechanisms, which may intersect at different points of the inflammatory process. Various autoimmune diseases include rheumatoid arthritis, ankylosing spondylitis, Guillain-Barre syndrome, as well as Hashimoto’s and Graves disease.

Read More »